Last reviewed · How we verify
Pneumococcal 13-valent Conjugate Vaccine
The Pneumococcal 13-valent Conjugate Vaccine, developed by Emory University, is a marketed product with a key composition patent expiring in 2028. The vaccine's primary strength lies in its broad coverage against 13 serotypes of Streptococcus pneumoniae, positioning it as a significant player in the prevention of pneumococcal diseases. The primary risk is the potential increase in competition post-patent expiry in 2028, which could impact market share and revenue.
At a glance
| Generic name | Pneumococcal 13-valent Conjugate Vaccine |
|---|---|
| Also known as | PCV13, Prevnar 13, PCV 13, PCV13 Vaccine, Prevnar 13® |
| Sponsor | Emory University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) (PHASE3)
- A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (PHASE1)
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (PHASE1, PHASE2)
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy (PHASE2)
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal 13-valent Conjugate Vaccine CI brief — competitive landscape report
- Pneumococcal 13-valent Conjugate Vaccine updates RSS · CI watch RSS
- Emory University portfolio CI